Clinical Trial Update: Health Economic Assessment of Tygacil® in the Treatment of Secondary Peritonitis in Intensive Care Units (ICUs)

View source ↗

Summary

Health economic assessment of tigecycline (Tygacil) for treating secondary peritonitis in ICU patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peritonitis

Drugs mentioned

• TYGACIL (tigecycline)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Peritonitis | Status: COMPLETED